Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

700 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-05-18

Study Completion Date

2024-03-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A multi-center, randomized, double-blind, bismuth-containing quadruple active comparator-controlled Phase 3 clinical study to evaluate the efficacy and safety of Rifasutenizol in combination with rabeprazole and amoxicillin in the primary treatment of participants with H. pylori infection using an adaptive design with sample size re-estimation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants

NCT06076694

Helicobacter Pylori Infection

COMPLETED PHASE2

A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules

NCT06076681

Helicobacter Pylori Infection

COMPLETED PHASE1/PHASE2

PPI-amoxicillin for H. Pylori Treatment

NCT05014685

Helicobacter Pylori Infection

UNKNOWN PHASE4

Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori

NCT04879992

Helicobacter Pylori Infection

COMPLETED NA

A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection

NCT04198363

Helicobacter Pylori

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects will be randomly assigned to test group or control group at a 1:1 ratio stratified by study site, and will receive Rifasutenizol capsules, rabeprazole sodium enteric-coated tablets, amoxicillin capsules combined with clarithromycin placebo tablets and bismuth potassium citrate placebo capsules (test group), or bismuth-containing quadruple regimen of amoxicillin capsules, clarithromycin tablets, rabeprazole sodium enteric-coated tablets and bismuth potassium citrate capsules combined with Rifasutenizol placebo capsules (control group) for 14 consecutive days.

carbon-13 (13C) UBT will be performed 4-6 weeks after the last dose to evaluate the eradication effect of H. pylori.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

H.Pylori Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test Group

Rifasutenizol capsules 400 mg + Rabeprazole sodium enteric-coated tablets 20 mg + Amoxicillin capsules 1 g + Bismuth potassium citrate placebo capsules + Clarithromycin placebo tablets, twice daily (BID) for 14 days

Group Type EXPERIMENTAL

Rifasutenizol capsules

Intervention Type DRUG

400 mg, BID, taken orally within half an hour after breakfast and dinner.

Rabeprazole sodium enteric-coated tablets

Intervention Type DRUG

20 mg, BID, taken orally within half an hour before breakfast and dinner.

Amoxicillin Capsules

Intervention Type DRUG

1 g, BID, taken orally within half an hour after breakfast and dinner.

Clarithromycin placebo tablets

Intervention Type DRUG

BID, taken orally within half an hour after breakfast and dinner.

Bismuth potassium citrate placebo capsules

Intervention Type DRUG

BID, taken orally within half an hour before breakfast and dinner.

Control Group

Amoxicillin capsules 1 g + Clarithromycin tablets 500 mg + Rabeprazole sodium enteric-coated tablets 20 mg + Bismuth potassium citrate capsules 240 mg + Rifasutenizol placebo capsules, BID for 14 days

Group Type ACTIVE_COMPARATOR

Rabeprazole sodium enteric-coated tablets

Intervention Type DRUG

20 mg, BID, taken orally within half an hour before breakfast and dinner.

Amoxicillin Capsules

Intervention Type DRUG

1 g, BID, taken orally within half an hour after breakfast and dinner.

Clarithromycin tablets

Intervention Type DRUG

500 mg, BID, taken orally within half an hour after breakfast and dinner.

Bismuth potassium citrate capsules

Intervention Type DRUG

240 mg, BID, taken orally within half an hour before breakfast and dinner.

Rifasutenizol placebo capsules

Intervention Type DRUG

BID, taken orally within half an hour before breakfast and dinner.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rifasutenizol capsules

400 mg, BID, taken orally within half an hour after breakfast and dinner.

Intervention Type DRUG

Rabeprazole sodium enteric-coated tablets

20 mg, BID, taken orally within half an hour before breakfast and dinner.

Intervention Type DRUG

Amoxicillin Capsules

1 g, BID, taken orally within half an hour after breakfast and dinner.

Intervention Type DRUG

Clarithromycin placebo tablets

BID, taken orally within half an hour after breakfast and dinner.

Intervention Type DRUG

Bismuth potassium citrate placebo capsules

BID, taken orally within half an hour before breakfast and dinner.

Intervention Type DRUG

Clarithromycin tablets

500 mg, BID, taken orally within half an hour after breakfast and dinner.

Intervention Type DRUG

Bismuth potassium citrate capsules

240 mg, BID, taken orally within half an hour before breakfast and dinner.

Intervention Type DRUG

Rifasutenizol placebo capsules

BID, taken orally within half an hour before breakfast and dinner.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TNP-2198 capsules Rabeprazole Amoxicillin Clarithromycin placebo Bismuth placebo Clarithromycin Bismuth Rifasutenizol placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Voluntarily sign the informed consent form.
* Age 18-65 years (inclusive), male or female.
* The result of 13C-UBT is positive (≥ 4 Delta Over Baseline), and the infection of H. pylori are confirmed by gastroscopic biopsy histology.
* Subjects agree to refrain from taking any antibiotics or traditional Chinese medicines with antibacterial effect, bismuth, and antacids (such as proton pump inhibitor, H2 receptor blocker, P-CAB) other than the study drugs during the Screening Period until the end of the study (Visit 5, i.e., Efficacy Evaluation Visit).
* Subjects and their heterosexual partners must agree to have no pregnancy plan and voluntarily take effective contraceptive measures during the trial and for at least 6 months after the end of the study medication.
* Willing to follow and able to complete all trial procedures.

Exclusion Criteria

* Allergy to any of the study drugs (rabeprazole, amoxicillin, clarithromycin, bismuth potassium citrate), allergic constitution (multiple drug and food allergies); or any contraindication to the use of rifamycin, nitroimidazoles or study drugs.
* History of H. pylori eradication therapy (including participation in other clinical trials for H. pylori eradication).
* Subjects with confirmed tuberculosis (TB) or Mycobacterium avium complex (MAC) infection or a history of TB or MAC infection.
* History of dysphagia or any gastrointestinal disorder affecting drug absorption.
* History of obstruction pyloric; or excessive gastric acid secretion (such as Zollinger-Ellison syndrome).
* History of gastric cancer.
* History of neoplasm malignant within 5 years prior to screening, with the exception of basal cell carcinoma or carcinoma cervix in situ treated without evidence of recurrence.
* History of esophageal or gastric surgery, except for simple repair of the perforated ulcer.
* History of substance abuse or drug use within 5 years prior to screening.
* Alcohol abuse or a history of alcohol abuse within 5 years prior to screening (average weekly consumption of ≥ 14 units of alcohol: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine/Chinese rice wine/rice wine);
* Presence of active gastric and/or duodenal ulcer.
* Anticoagulant therapy or long-term treatment with nonsteroidal anti-inflammatory drugs.
* Treatment with any other investigational new drugs within 4 weeks prior to the Screening Period.
* Any prohibited medications or non-drug therapies as specified in the protocol (see Section 10.3).
* White blood cell count or neutrophil count below the lower limit of normal range.
* Anemia (hemoglobin \< 90 g/L).
* Aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, or serum creatinine above the upper limit of normal range.
* Test positive for hepatitis B surface antigen, hepatitis C antibody, AIDS antibody, or microspironema pallidum antibody.
* Abnormal ECG with clinical significance.
* Female subjects who are pregnant, lactating, or have a positive urine pregnancy result during the Screening Period.
* Inability to communicate with the Investigator and to comply with the study requirements.
* Other conditions considered inappropriate to participate in this study by the Investigator, e.g., the subject has a history of severe central nervous system, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urological, endocrine, or hematological diseases, or has clinical manifestations of these diseases.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No